Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Actinogen Medical ( (AU:ACW) ) has provided an update.
Actinogen Medical Limited has applied to the ASX for quotation of 82,093 new fully paid ordinary shares, to be issued on 2 January 2026 under the ticker ACW. The modest increase in quoted securities reflects the conversion or exercise of existing options or other convertible instruments, slightly expanding the company’s share base and providing incremental capital or aligning incentives for stakeholders, without indicating any major strategic shift in its operations.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is an Australian biotechnology company listed on the ASX under the code ACW. The company operates in the medical and life sciences sector, focusing on the development of pharmaceutical and therapeutic products, with a primary presence in the Australian capital markets.
Average Trading Volume: 4,492,826
Technical Sentiment Signal: Buy
Current Market Cap: A$194.4M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.